Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma

Published:2009-04-24 Issue:5 Volume:57 Page:335-340
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Zinzani P. L.,Baccini C.,Zaccaria A.,Visani G.,Buzzi M.,Morelli A.,Molinari A. L.,Salvucci M.,Bendandi M.,Rubboli D.,Gherlinzoni F.,Zanchini R.,Tura S.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1996.tb01390.x/fullpdf

Reference30 articles.

1. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma;Rehn;Hematol Oncol,1990

2. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse /tumour progression in low-grade B-cell lymphoma;Holte;Int J Cancer,1989

3. Evaluation of bcl-2 protein expression and 14; 18 translocation as prognostic markers in follicular lymphoma;Pezzella;Br J Cancer,1992

4. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma;Leonard;Ann Oncol,1991

5. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma;Motokura;Leuk Lymph,1995

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas;Leukemia & Lymphoma;2015-10-12

2. Prognostic Factors in Follicular Lymphoma;Journal of Clinical Oncology;2010-06-10

3. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study;Carcinogenesis;2007-03

4. The Role of Bortezomib in the Treatment of Lymphoma;Cancer Investigation;2007-01

5. Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity;Journal of Clinical Oncology;2006-05-01